Janssen to Showcase Robust Oncology Portfolio at ESMO 2018 Congress

San Francisco, CA USA (UroToday.com) --  The Janssen Pharmaceutical Companies of Johnson & Johnson will present updates from across its oncology portfolio at the European Society for Medical Oncology (ESMO) 2018 annual congress, taking place on 19-23 October in Munich, Germany. Phase 3 data from the SPARTAN study reporting health-related quality of life outcomes in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide will be included in a poster session, with a further poster session highlighting data for ZYTIGA®  (abiraterone acetate) in metastatic hormone-sensitive prostate cancer. For erdafitinib in metastatic bladder cancer, a poster session will include an overview of the Phase 3 clinical trial design, and results from a Phase 2a study in advanced cholangiocarcinoma will be featured in a poster discussion.

Abstracts include clinical updates across solid tumor targeted therapies
  • Quality of life outcomes from Phase 3 SPARTAN clinical trial of apalutamide in non- metastatic castration-resistant prostate cancer
  • Practice informing PSA dynamics data from pivotal Phase 3 LATITUDE trial assessing ZYTIGA® plus prednisone and Androgen Deprivation Therapy (ADT) in metastatic hormone-sensitive prostate cancer
  • Presentation of erdafitinib Phase 3 study design in metastatic or surgically unresectable (M/UR) urothelial carcinoma
“We are proud to share such robust data and across a range of tumor types at this year’s ESMO congress,” said Dr. Ivo Winiger-Candolfi M.D., Europe, Middle East and Africa Oncology Solid Tumor Therapy Area Lead, Cilag GmbH International. “We are particularly excited to present health-related quality of life data from the SPARTAN trial, results that were recently published in The Lancet Oncology. Transforming patient outcomes is a key commitment for us at Janssen, and helping patients maintain quality of life while on treatment can be as important as their clinical outcome.”
Company-sponsored abstracts to be presented at the meeting include:


Abstract #804P : “Health-Related Quality of Life (HRQoL) After Progressive Disease (PD) in SPARTAN: a Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men with Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)” 
Poster display session Monday 22 October 12:45 - 13:45 Hall A3

Abstract #806P : “Relationship Between Apalutamide (APA) Exposure and Metastasis-Free Survival (MFS) in Patients (pts) With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC) From SPARTAN”

Poster display session Monday 22 October Time: 12:45 - 13:45 Hall A3

Abstract #797PD : “LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression- free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT + abiraterone acetate and prednisone (AAP) or placebo (PBO)”
Poster discussion session - genitourinary tumours, prostate (ID 167) Sunday 21 October 09:15 - 10:30 ICM - Room 14b

Abstract #920TiP : “Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Patients (pts) With Metastatic or Surgically Unresectable (M/UR) Urothelial Carcinoma(UC) and Selected FGFR Gene Alterations (FGFRalt): the Phase 3 THOR Study”
Poster display session Monday 22 October 12:45-13:45 Hall A3

Abstract #624PD : “Preliminary Results of a Phase2a Study to Evaluate the Clinical Efficacy and Safety of Erdafitinib in Asian Patients with Biomarker-Selected Advanced Cholangiocarcinoma (CCA)” 
Poster discussion session: gastrointestinal, non- colorectal 1 (ID 261) Friday 19 October 15:45 - 17:20 Hall B3 - Room 21


Abstract #834P : “Interim Results of a Phase 1b Study of Niraparib plus Androgen Receptor- Targeted Therapy in Men with Metastatic Castration-Resistant Prostate Cancer” 
Poster display session Monday 22 October 12:45-13:45 Hall A3

Abstract #1497P “JNJ-61186372 (JNJ-372), an EGFR-cMET Bispecific Antibody, in Advanced Non- Small Cell Lung Cancer (NSCLC): An Update on Phase 1 Results”
Poster display session Saturday 20 October 12:30-13:30 Hall A3

VELCADE® (bortezomib) : 
Abstract #1004O : “Final Overall Survival Results of Frontline Bortezomib plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) vs R-CHOP in Transplantation-ineligible Patients (Pts) with Newly Diagnosed Mantle-Cell Lymphoma (MCL): A Randomized, Open- Label, Phase 3 (LYM3002) Study” Proffered paper session Sunday 21 October 11:00 – 11:15 Hall A3

Further Related Content:
Complete ESMO 2018 Conference Coverage